OptiBiotix Health PLC US launch of LPLDL® with Seed Health (5546Q)
June 07 2018 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 5546Q
OptiBiotix Health PLC
07 June 2018
7 June 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
US launch of LP(LDL) (R) with Seed Health
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces the US launch of a product containing its
cholesterol and blood pressure reducing strain LP(LDL) (R) with
Seed Health ("Seed").
OptiBiotix previously announced (RNS: 22 May 2018) that it has
entered into a non-exclusive agreement with Seed to produce,
promote, market and commercialise products containing LP(LDL) (R)
in the USA. Seed will market its first product containing LP(LDL)
(R) under the brand name Daily Synbiotic(TM) and promote it
directly to consumers on its online platform www.seed.com.
Seed was launched on 6 June 2018, with the aim of setting a new
standard of scientific rigor and consumer education in the $38
billion global probiotics industry. Daily Synbiotic(TM), its first
product, is targeted at the US probiotic market, one of the largest
and fastest growing probiotic markets in the world, with
supplements alone accounting for $2.06 billion sales, and a
projected 55% growth per annum to $3.3 billion by 2021*.
Seed's team is led by co-founders and co-CEOs, Ara Katz and Raja
Dhir, and includes Chief Scientist, Dr. Gregor Reid, a pioneer in
the field of probiotics. Seed's Scientific Advisory Board includes
some of the world's leading microbiome scientists with expertise in
microbiology, immunology, genetics, metabolomics, gastroenterology,
paediatrics and women's health.
*Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING
THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June
2017).
Stephen O'Hara, CEO of OptiBiotix, commented: "We are excited to
see the launch of products containing our cholesterol reducing
LP(LDL) (R) strain in the USA, the world's largest and fastest
growing probiotic market. The launch with Seed substantiates the
science behind LP(LDL) (R) and helps build the LP(LDL) (R) brand in
the consumer healthcare market around the world. We hope this will
be the first of many product launches of multiple formulations and
presentations of LP(LDL) (R) as the active component in a wide
range of products in the USA and around the world."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSSWFIMFASEEM
(END) Dow Jones Newswires
June 07, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024